Information Provided By: 
Fly News Breaks for February 12, 2019
MEIP
Feb 12, 2019 | 18:54 EDT
Target $5.50.BTIG analyst Thomas Shrader initiated MEI Pharma with a Buy rating and a price target of $5.50, saying the company offers an "interesting set of assets for Hematological Cancers" that have a "good chances of success in important markets." Shrader sees its MEI-401 as the "best-in-class" program with "impressive data to date making safety study a key readout after its novel trial design was vetted by the FDA.
News For MEIP From the Last 2 Days
There are no results for your query MEIP
